Tango Therapeutics (TNGX) Free Cash Flow (2020 - 2026)

Tango Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$44.4 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 6.25% year-over-year to -$44.4 million; the TTM figure through Mar 2026 stood at -$142.5 million (down 4.85% YoY), while the FY2025 annual figure was -$139.9 million, down 5.81% from the prior year.
• Free Cash Flow was -$44.4 million for Q1 2026 at Tango Therapeutics, down from -$29.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$23.9 million in Q2 2024 to a low of -$44.4 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$32.5 million across 5 years, with a median of -$31.5 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow sank 312.71% in 2022, then gained 20.07% in 2023.
• A 5-year view of Free Cash Flow shows it stood at -$29.3 million in 2022, then rose by 5.51% to -$27.7 million in 2023, then tumbled by 35.04% to -$37.4 million in 2024, then climbed by 19.94% to -$29.9 million in 2025, then tumbled by 48.16% to -$44.4 million in 2026.
• The last three Free Cash Flow figures came in at -$44.4 million (Q1 2026), -$29.9 million (Q4 2025), and -$31.5 million (Q3 2025), per Business Quant data.